Evidence map›Paper›PMID 25750704›Full record

ReviewComputational and structural biotechnology journal2015

Neuroprotection Mediated by P2Y13 Nucleotide Receptors in Neurons.

Raquel Pérez-Sen, M José Queipo, Verónica Morente, Felipe Ortega, Esmerilda G Delicado, M Teresa Miras-Portugal

Open access · goldAbstract readReview
In one paragraph

Review in Computational and structural biotechnology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Silencing P2YCell communication and signaling : CCS · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Update of P2Y receptor pharmacology: IUPHAR Review 27.British journal of pharmacology · 2020
    Review
  15. Dual-Specificity Phosphatase Regulation in Neurons and Glial Cells.International journal of molecular sciences · 2019
    Review
  16. Article
  17. P2YMolecular neurobiology · 2018
    Article
  18. Purinergic Signalling: Therapeutic Developments.Frontiers in pharmacology · 2017
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Raquel Pérez-SenBiochemistry Department, School of Veterinary Sciences, Complutense University of Madrid, Institute of Neurochemistry (IUIN), Madrid, Spain.
M José QueipoBiochemistry Department, School of Veterinary Sciences, Complutense University of Madrid, Institute of Neurochemistry (IUIN), Madrid, Spain.
Verónica MorenteBiochemistry Department, School of Veterinary Sciences, Complutense University of Madrid, Institute of Neurochemistry (IUIN), Madrid, Spain.
Felipe OrtegaBiochemistry Department, School of Veterinary Sciences, Complutense University of Madrid, Institute of Neurochemistry (IUIN), Madrid, Spain.
Esmerilda G DelicadoBiochemistry Department, School of Veterinary Sciences, Complutense University of Madrid, Institute of Neurochemistry (IUIN), Madrid, Spain.
M Teresa Miras-PortugalBiochemistry Department, School of Veterinary Sciences, Complutense University of Madrid, Institute of Neurochemistry (IUIN), Madrid, Spain.
Universidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ADP-specific P2Y13 receptor constitutes one of the most recently identified nucleotide receptor and the understanding of their physiological role is currently under investigation. Cerebellar astrocytes and granule neurons provide excellent models to study P2Y13 expression and function since the first identification of ADP-evoked calcium responses not attributable to the related P2Y1 receptor was performed in these cell populations. In this regard, all responses induced by ADP analogues in astrocytes resulted to be Gi-coupled activities mediated by P2Y13 instead of P2Y1 receptors. Similarly, both glycogen synthase kinase-3 (GSK3) and ERK1/2 signaling triggered by 2MeSADP in cerebellar granule neurons were also dependent on Gi-coupled receptors, and mediated by PI3K activity. In granule neurons, P2Y13 receptor was specifically coupled to the main neuronal survival PI3K/Akt-cascade targeting GSK3 phosphorylation. GSK3 inhibition led to nuclear translocation of transcriptional targets, including β-catenin and Nrf2. The activation of the Nrf2/heme oxygenase-1 (HO-1) axis was responsible for the prosurvival effect against oxidative stress. In addition, P2Y13-mediated ERK1/2 signaling in granule neurons also triggered activation of transcription factors, such as CREB, which underlined the antiapoptotic action against glutamate-induced excitotoxicity. Finally, a novel signaling mechanism has been recently described for a P2Y13 receptor in granule neurons that involved the expression of a dual protein phosphatase, DUSP2. This activity contributed to regulate MAPK activation after genotoxic stress. In conclusion, P2Y13 receptors harbored in cerebellar astrocytes and granule neurons exhibit specific signaling properties that link them to specialized functions at the level of neuroprotection and trophic activity in both cerebellar cell populations.

Indexed as

DUSPERK1/2 signalingGSK3 signalingMAPK protein phosphatasesNeuroprotectionNucleotide receptorsP2Y13 receptor

Identifiers

PMID25750704
PMCPMC4348571
OpenAlexW2050892991

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.